The progress of one of the company's clinical programs is being delayed.
News & Analysis: Selecta Biosciences, Inc. Common Stock
SELB earnings call for the period ending September 30, 2020.
"Buy low, sell high" is easy when stocks are cheap. The hard part is finding inexpensive healthcare stocks that are more than just speculative trades.
Disappointing phase 2 data casts doubt on SEL-212's future.
SELB earnings call for the period ending June 30, 2020.
These two healthcare stocks are risky, but they have much better chances of success than penny stocks.
A bullish article is sending shares higher.
A licensing deal for a late-stage asset failed to impress Wall Street. One analyst went as far as downgrading the biopharma stock.
SELB earnings call for the period ending March 31, 2020.
Selecta in-licenses a promising cancer therapeutic. But don't get too carried away by today's move higher.